Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757769 | 0.86 | PTGDR2 (0.47) | MEN1KMT2APTGDR2KDM4EALDH1A1 | |
| SCHEMBL1757628 | 0.72 | ALDH1A1 (0.70) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL1757523 | 0.70 | KDM4E (0.49) | PTGDR2KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1757940 | 0.64 | PTGDR2 (0.56) | MEN1KMT2APTGDR2KDM4ESMN1; SMN2 | |
| SCHEMBL27268228 | 0.61 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19609936 | 0.61 | HTR2A (0.32) | — | |
| SCHEMBL22266117 | 0.61 | ALDH1A1 (0.58) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL30529271 | 0.61 | GRIA1 (0.42) | ALDH1A1HPGDSMN1; SMN2NPSR1TP53 | |
| SCHEMBL6969733 | 0.60 | CACNA1G (0.46) | ALDH1A1HTT | |
| SCHEMBL2556351 | 0.57 | DPP4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | MEN1 3026/4885KMT2A 3787/4885PTGDR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.